Top Buy Stocks
Sign In
NASDAQ:DVAX
Dynavax Technologies Corporation Stock News
$9.85
+0.440 (+4.68%)
At Close: May 12, 2025
Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director Nominees Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Toda
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
01:00pm, Thursday, 08'th May 2025
Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum
04:45pm, Wednesday, 07'th May 2025
Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Short-Term Return Urges Stockholders to Vote "FOR" All F
Dynavax Technologies Corporation (DVAX) Q1 2025 Earnings Call Transcript
07:34pm, Tuesday, 06'th May 2025
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ry
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
06:15pm, Tuesday, 06'th May 2025
Dynavax Technologies (DVAX) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $0.07 per share a year ago.
Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs
04:01pm, Tuesday, 06'th May 2025
Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growth Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025 New pand
Over half of American adults do not know chronic hepatitis B can cause liver disease such as cirrhosis and liver cancer Half of American adults were unaware that anyone can be at risk for the hepatiti
Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy
07:30am, Tuesday, 29'th Apr 2025
Mails Letter to Stockholders Urging Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card EMERYVILLE, Calif. , April 29, 2025 /PRNewswire/ -- Dynavax Technologies Corpor
Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
04:00pm, Tuesday, 22'nd Apr 2025
EMERYVILLE, Calif. , April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wi
Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders
04:05pm, Monday, 21'st Apr 2025
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DV
Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders
07:15am, Thursday, 17'th Apr 2025
Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Highlights Record Financial and Operational Results, Balanced Capital Allocation Strategy andMeaningful Board
Deep Track Capital Comments on Dynavax Technologies' Rejection of Most Recent Settlement Offer
08:00am, Wednesday, 16'th Apr 2025
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”) is one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:
Dynavax Files Preliminary Proxy Statement
05:40pm, Thursday, 03'rd Apr 2025
Dynavax's Board is Overseeing Record Operational and Financial Performance Outlines Extensive Engagement with Deep Track and Multiple Attempts to Reach a Resolution EMERYVILLE, Calif. , April 3, 2025
Why Dynavax Technologies (DVAX) Stock Might be a Great Pick
11:45am, Thursday, 20'th Mar 2025
Dynavax Technologies (DVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase
06:00am, Thursday, 06'th Mar 2025
Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure $225 million of convertible notes due in 2030 issued, inc
